277 related articles for article (PubMed ID: 22525221)
1. Processes of psoriasis health care in Germany--long-term analysis of data from the statutory health insurances.
Augustin M; Glaeske G; Schäfer I; Rustenbach SJ; Hoer A; Radtke MA
J Dtsch Dermatol Ges; 2012 Sep; 10(9):648-55. PubMed ID: 22525221
[TBL] [Abstract][Full Text] [Related]
2. Drug supply for children with psoriasis in Germany.
Augustin M; Reich K; Glaeske G; Kämpfe S; Radtke MA; Gerdau-Heitmann C; Schicktanz C; Schäfer I
J Dtsch Dermatol Ges; 2013 Aug; 11(8):751-5. PubMed ID: 23718227
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
4. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
[TBL] [Abstract][Full Text] [Related]
5. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
6. Drug supply for psoriasis - results from a national pharmacy network.
Franzke N; Montenbruck M; Langenbruch AK; Beikert FC; Kresken J; Augustin M
J Dtsch Dermatol Ges; 2013 Jul; 11(7):638-43. PubMed ID: 23464851
[TBL] [Abstract][Full Text] [Related]
7. Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.
Augustin M; Reich K; Reich C; Purwins S; Jeff Rustenbach S; Schäfer I; Radtke M
J Dtsch Dermatol Ges; 2008 Aug; 6(8):640-5. PubMed ID: 18801145
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of psoriasis with biologics: a survey of dermatological and rheumatological practice at Reims University Hospital].
Adnot-Desanlis L; Brochot P; Eschard JP; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2012 May; 139(5):355-62. PubMed ID: 22578339
[TBL] [Abstract][Full Text] [Related]
9. Juvenile psoriasis: rewarding endeavours in contemporary dermatology and pediatrics.
Radtke MA; Fölster-Holst R; Beikert F; Herberger K; Augustin M
G Ital Dermatol Venereol; 2011 Feb; 146(1):31-45. PubMed ID: 21317855
[TBL] [Abstract][Full Text] [Related]
10. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States.
Kulkarni AS; Balkrishnan R; Richmond D; Pearce DJ; Feldman SR
J Am Acad Dermatol; 2005 Jan; 52(1):27-31. PubMed ID: 15627077
[TBL] [Abstract][Full Text] [Related]
11. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States.
Lin HC; Lucas PT; Feldman SR; Balkrishnan R
J Dermatolog Treat; 2012 Jun; 23(3):196-202. PubMed ID: 21254887
[TBL] [Abstract][Full Text] [Related]
12. Trends in pediatric psoriasis outpatient health care delivery in the United States.
Vogel SA; Yentzer B; Davis SA; Feldman SR; Cordoro KM
Arch Dermatol; 2012 Jan; 148(1):66-71. PubMed ID: 21931013
[TBL] [Abstract][Full Text] [Related]
13. Trends in older adult psoriasis outpatient health care practices in the United States.
Wong JW; Davis SA; Feldman SR; Koo JY
J Drugs Dermatol; 2012 Aug; 11(8):957-62. PubMed ID: 22859241
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals.
De Jager ME; Van de Kerkhof PC; De Jong EM; Seyger MM
J Dermatolog Treat; 2009; 20(5):254-8. PubMed ID: 19418330
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
[TBL] [Abstract][Full Text] [Related]
16. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiology of psoriasis in Germany--analysis of secondary health insurance data].
Schäfer I; Rustenbach SJ; Radtke M; Augustin J; Glaeske G; Augustin M
Gesundheitswesen; 2011 May; 73(5):308-13. PubMed ID: 20544588
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of psoriasis therapy with etanercept in Germany.
Heinen-Kammerer T; Daniel D; Stratmann L; Rychlik R; Boehncke WH
J Dtsch Dermatol Ges; 2007 Sep; 5(9):762-8. PubMed ID: 17760896
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis treatment in the United States at the end of the 20th century.
Pearce DJ; Stealey KH; Balkrishnan R; Fleischer AB; Feldman SR
Int J Dermatol; 2006 Apr; 45(4):370-4. PubMed ID: 16650160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
